The Japanese Patent Office issued an Appeal Decision granting a patent for REQORSA used with PD-L1 antibodies, while the European Patent Office granted a patent covering REQORSA in combination with PD-1 antibodies. Both patents are exclusively licensed to Genprex, extending protection for these therapeutic combinations in two major markets.

These awards build on existing U.S. and Korean patents for REQORSA with PD-L1 antibodies and U.S., Japan, Mexico, Russia, Australia, Chile, China, Singapore and European patents for PD-1 combinations, with an Australian grant pending. The new grants reinforce a comprehensive IP framework across key jurisdictions.

The patents encompass the Acclaim-3 Phase 1/2 trial in extensive-stage small cell lung cancer, which administers REQORSA with Tecentriq as maintenance therapy until disease progression or unacceptable toxicity. The study’s Phase 2 expansion targets an 18-week progression-free survival endpoint with interim analysis after 25 patients.

By securing global patent coverage in Japan and Europe, Genprex strengthens its negotiation stance for immunotherapy partnerships and de-risks future oncology revenue. Enhanced IP rights in these territories may improve licensing opportunities and support long-term commercialization plans.